15 completed, 4 terminated, 4 unknown, 1 active not recruiting. 26 Phase 2, 6 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 26 | Completed 15, Terminated 4, Unknown 4, Active not recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 3 | 6 | Completed 4, Terminated 1, Unknown 1 |
| Phase 1 | 3 | Completed 2, Recruiting 1 |
Follow lanreotide: new trials by email Literature Review of lanreotide trials Research Report on lanreotide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors Cabozantinib, Lanreotide - Neuroendocrine Tumors,Gastroenteropancreatic | Phase 1 / Phase 2 | Recruiting | National Health Research Institutes, Taiwan | 49 | 2021-09-17 | 2026-04-09 |
| A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET Cabozantinib, Lanreotide - Metastatic Well Differentiated Neuroendocrine Neoplasm, Neuroendocrine Tumors | Phase 2 | Unknown | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 69 | 2020-06-20 | 2021-09-05 |
| Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands IONIS GHR-LRx, Somatostatin Receptor Ligand (SRL) - Acromegaly | Phase 2 | Completed | Ionis Pharmaceuticals, Inc. | 39 | 2019-07-25 | 2023-03-22 |
| LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA) Lanreotide - Paraganglioma, Pheochromocytoma | Phase 2 | Active not recruiting | Antonio Fojo | 10 | 2019-06-17 | 2026-03-02 |
| A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula Lanreotide Prefilled Syringe - Pancreatic Leak, Pancreatic Fistula | Phase 2 | Completed | University of Washington | 114 | 2018-02-20 | 2022-06-16 |
| Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres Lanreotide, Y-90 microspheres - Neuroendocrine Tumors, Gastrointestinal Neoplasms | Phase 2 | Terminated | SCRI Development Innovations, LLC | 6 | 2017-07-28 | 2023-12-05 |
| Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors Lanreotide, Pembrolizumab - Gastroenteropancreatic Neuroendocrine Tumors | Phase 1 / Phase 2 | Completed | Duke University | 22 | 2017-07-01 | 2023-06-29 |
| Lanreotide in the Treatment of Small Bowel Motility Disorders Lanreotide - Gastrointestinal Motility Disorder, Intestinal Disease | Phase 2 | Completed | Northwell Health | 12 | 2017-05-11 | 2021-01-15 |
| Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors. Lanreotide (Autogel formulation) and Temozolomide - Neuroendocrine Tumours | Phase 2 | Completed | Ipsen | 40 | 2016-07-01 | 2020-10-01 |
| A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors Ramucirumab, Somatostatin Analog - Carcinoid Tumors | Phase 2 | Completed | Dana-Farber Cancer Institute | 43 | 2016-06-14 | 2025-02-19 |
| Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues Lanreotide - Carcinoma, Merkel Cell | Phase 2 | Completed | University Hospital, Grenoble | 35 | 2015-04-01 | 2017-10-18 |
| Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly Lanreotide PRF - Acromegaly | Phase 1 / Phase 2 | Completed | Ipsen | 28 | 2015-03-01 | 2019-04-25 |
| A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET) lanreotide, Placebo - Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours | Phase 2 / Phase 3 | Terminated | Federation Francophone de Cancerologie Digestive | 53 | 2015-01-01 | 2023-01-18 |
| Quality of Life in Patients With Inoperable Malignant Bowel Obstruction lanreotide (Autogel formulation) - Intestinal Obstruction | Phase 2 | Terminated | Ipsen | 43 | 2015-01-01 | 2019-11-22 |
| Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y Gastrojejunostomy Lanreotide - Acid Reflux Esophagitis, Non-acid Reflux Esophagitis | Phase 2 | Unknown | Universitair Ziekenhuis Brussel | 10 | 2014-04-01 | 2014-02-04 |
| A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors Lanreotide, Placebo (for sunitinib), Sunitinib - Carcinoid Tumors | Phase 2 | Unknown | GERCOR - Multidisciplinary Oncology Cooperative Group | 44 | 2013-01-07 | 2017-01-31 |
| Efficacy and Safety of Lanreotide 120 Milligram (mg) as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients Lanreotide (acetate) - Malignant Intestinal Obstruction | Phase 2 | Completed | University Hospital, Ghent | 40 | 2009-10-01 | 2014-12-05 |
| Lanreotide Autogel in the Symptomatic Treatment of Refractory Diarrhea lanreotide (Autogel formulation) - Diarrhea | Phase 2 / Phase 3 | Completed | Ipsen | 42 | 2009-07-01 | 2019-01-15 |
| Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG) lanreotide (Autogel formulation) - Acromegaly | Phase 2 | Withdrawn | Ipsen | 2008-05-01 | 2019-08-05 | |
| SOMATULINE Autogel 90 mg IN DUMPING SYNDROME Lanreotide 90 mg slow release formulation, Placebo - Dumping Syndrome | Phase 2 | Completed | Universitaire Ziekenhuizen KU Leuven | 24 | 2008-04-01 | 2023-01-27 |
Showing 20 of 26. Sign in to see all of them.
Neuroendocrine Tumors (5) · Acromegaly (4) · Carcinoid Tumor (3) · Hepatomegaly (2) · Liver Diseases (2) · Neoplasm Metastasis (2) · Polycystic liver disease (2) · Bile Reflux (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Merkel Cell (1) · Diarrhea (1) · Dumping Syndrome (1) · Esophagitis, Peptic (1) · Fistula (1) · Gastro-enteropancreatic neuroendocrine tumor (1)
Ipsen (8) · Radboud University Medical Center (2) · Antonio Fojo (1) · Dana-Farber Cancer Institute (1) · Duke University (1) · Federation Francophone de Cancerologie Digestive (1) · Federico II University (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · GERCOR - Multidisciplinary Oncology Cooperative Group (1) · Ionis Pharmaceuticals, Inc. (1) · National Health Research Institutes, Taiwan (1) · Northwell Health (1) · SCRI Development Innovations, LLC (1) · Universitair Ziekenhuis Brussel (1) · Universitaire Ziekenhuizen KU Leuven (1)
Belgium (9) · United States (8) · France (5) · Italy (5) · Netherlands (4) · Germany (3) · Spain (3) · United Kingdom (3) · Czechia (2) · Hungary (2) · Lithuania (2) · Poland (2) · Russia (2) · Hong Kong (1) · Mexico (1)
Frederik Nevens, MD, PhD (2) · Loes van Keimpema, MSc (2) · Annamaria Colao, MD, PhD (1) · Antonio Fojo, MD, PhD (1) · Come Lepage, Pr (1) · David Spigel, M.D. (1)
PMID 10207464, PMID 10517918, PMID 10573522, PMID 10811995, PMID 10984283, PMID 12066229, PMID 12198662, PMID 12540801, PMID 12591191, PMID 12759473, PMID 12902325, PMID 14762851, PMID 14974910, PMID 15246216, PMID 15588232, PMID 16801334, PMID 16953241, PMID 17589893, PMID 18810319, PMID 19639415, PMID 21306237, PMID 24053191, PMID 24405892, PMID 25014687, PMID 25956467, PMID 27423779, PMID 34664531, PMID 36044870, PMID 36087395, PMID 37752423, PMID 39356039, PMID 39834129, PMID 42791653, PMID 6087395, PMID 7568806, PMID 7758431, PMID 8213718, PMID 8635123, PMID 8675143, PMID 8709253, PMID 8903411, PMID 8938543, PMID 9438850, PMID 9593409, PMID 9797392, PMID 9934776
2014 (3), 2004 (2), 2019 (2), 2008 (1), 2009 (1)